The Indian government has given its crucial approval to Novo Nordisk's prominent obesity medication, Wegovy, for a new indication: the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This serious form of fatty liver disease affects a substantial portion of the Indian population, presenting a significant opportunity for the pharmaceutical giant.
Wegovy's Expanded Role in India
The Central Drugs Standard Control Organisation (CDSCO) specifically approved the 2.4 mg semaglutide injection, known commercially as Wegovy, for MASH treatment. Semaglutide, the active ingredient in Wegovy, is already approved in India and multiple international markets for chronic weight management. This new approval marks a pivotal moment, broadening the drug's therapeutic scope within the country.
Novo Nordisk estimates that approximately two in three people in India suffer from some form of fatty liver disease. This vast patient demographic highlights the immense potential for Wegovy in addressing a widespread and often silent health condition.
Understanding MASH and Market Dynamics
Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by the accumulation of fats in the liver, leading to inflammation and potential liver damage. If left unaddressed, MASH can progress to more severe complications, including cirrhosis and liver failure. The disease often presents without noticeable symptoms until it reaches an advanced stage, making early intervention and effective treatments critical.
In the Indian market, Novo Nordisk faces competition for its semaglutide-based products. Rivals include Eli Lilly's Mounjaro and various lower-cost generic obesity medications launched by local pharmaceutical companies such as Dr. Reddy's and Sun Pharma. Despite the competitive landscape, Novo Nordisk reported strong initial sales, with around 76,000 units of Wegovy sold in India during the first half of 2026.